Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships

McGill University

$105,000.00

Local dissociation of DNA/DNA and DNA/RNA from the ribonuclease H active site of HIV-1 reverse transcriptase: Implications for (+)-strand DNA synthesis and drug design

FY 2008-09

Summary
The Human Immunodeficiency Virus type-1 (HIV-1) affects approximately 33 million people globally, with around 2.7 million new cases reported annually, according to UNAIDS. The enzyme used by the HIV-1 virus to replicate itself is called reverse transcriptase, or RT. RT is responsible for converting the HIV-1 genome (single strand RNA) into a form that can be integrated into our own DNA (double strand DNA). To accomplish this RT contains two active centers, located in different areas of the enzyme. The first is a polymerase active site, that synthesizes new DNA, while the second is a ribonuclease H active site, that degrades the old RNA. During called reverse transcription, RT must bind in a very specific way to the RNA to begin the synthesis of the second DNA strand, or (+)-strand. How RT binds during the initiation of (+)-strand DNA synthesis is currently a topic of debate in the field. One theory states that RT is unable to bind the RNA so that both of its two active centers are in contact with the RNA at the same time, and that it must "toggle" between them in order to properly initiate (+)-strand synthesis. Another states that both active sites can bind the RNA simultaneously. In this study, we attempt to elucidate which theory is correct by employing a wide variety of biochemical techniques. Understanding how RT binds RNA during this very sensitive and important step in reverse transcription is critical to the drug development effort. Since resistance to all clinically relevant HIV drugs currently presents a serious problem in tackling the HIV/AIDS epidemic, new drug targets such as the initiation of (+)-strand DNA synthesis are essential to increase the clinical options of patients and physicians, as well as advancing the field of HIV chemotherapeutics.
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
184425
Name
Beilhartz Greg L
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Local dissociation of DNA/DNA and DNA/RNA from the ribonuclease H active site of HIV-1 reverse transcriptase: Implications for (+)-strand DNA synthesis and drug design
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Drug Development; Drug Resistance; Hiv; Inhibitors; Mechanism; Mutation; Nucleic Acids; Reverse Transcriptase; Rnase H; Virology
Abstract
The Human Immunodeficiency Virus type-1 (HIV-1) affects approximately 33 million people globally, with around 2.7 million new cases reported annually, according to UNAIDS. The enzyme used by the HIV-1 virus to replicate itself is called reverse transcriptase, or RT. RT is responsible for converting the HIV-1 genome (single strand RNA) into a form that can be integrated into our own DNA (double strand DNA). To accomplish this RT contains two active centers, located in different areas of the enzyme. The first is a polymerase active site, that synthesizes new DNA, while the second is a ribonuclease H active site, that degrades the old RNA. During called reverse transcription, RT must bind in a very specific way to the RNA to begin the synthesis of the second DNA strand, or (+)-strand. How RT binds during the initiation of (+)-strand DNA synthesis is currently a topic of debate in the field. One theory states that RT is unable to bind the RNA so that both of its two active centers are in contact with the RNA at the same time, and that it must "toggle" between them in order to properly initiate (+)-strand synthesis. Another states that both active sites can bind the RNA simultaneously. In this study, we attempt to elucidate which theory is correct by employing a wide variety of biochemical techniques. Understanding how RT binds RNA during this very sensitive and important step in reverse transcription is critical to the drug development effort. Since resistance to all clinically relevant HIV drugs currently presents a serious problem in tackling the HIV/AIDS epidemic, new drug targets such as the initiation of (+)-strand DNA synthesis are essential to increase the clinical options of patients and physicians, as well as advancing the field of HIV chemotherapeutics.
Competitiondate
200810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Beilhartz, Greg L
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
McGill University - $105,000 Grant (2008-09) | Canada Spends